Palatin Technologies, Inc. (NYSEMKT:PTN) recently announced that it will soon decide on the day to have a conference call and audio webcast for discussion of licensed agreement with AMAG Pharmaceuticals, Inc. The agreement, which is expected to reach its destination by March 2017, gave an exclusive right to Palatin Technologies regarding commercialization of Rekynda™ (bremelanotide).
A successful agreement coming to close
The agreement allowed Palatin Technologies the exclusive license for development and commercialization of Rekynda™ in North America. This is an investigational product, specifically meant for on-demand treatment of HSSD or hypoactive sexual desire disorder among women going through pre-menopausal stage.
During the conference call, which it shall schedule in the quarter to come, Palatin would probably discuss about how the agreement worked out for both companies and what would be the future course of action, as far as the agreement is concerned.
Where will be the agreement take Palatin’s role for Rekynda?
In the conference call, the company will discuss about its future role in development or seeking regulatory nod for Rekynda. There are hints of potential licensing right outside the set defined geographical boundaries of North America.
If the company decides to extend this agreement and seek rights for other regions as well, it would give it a scope to enter new markets in Pharma industry. The company will also be able to establish ground for its upcoming drugs or treatments.
Meanwhile, the company also announced that the call will anticipate the company’s future steps for its ongoing or to-be started drug development programs. This includes discussion over melanocortin receptor-1 agonist peptides, meant for the inflammatory and dermatologic disease treatment.
THE MORNING REPORT
Start your workday the right way with the news that matters most.
Your information is 100% secure with us and will never be shared Disclaimer & Privacy Policy
The programs to be discussed also include melanocortin receptor-4 agonist compounds (for diabetes and obesity treatment) along with natriuretic peptide receptor-A agonist compounds (for cardiovascular and pulmonary indications treatment).
The company said that the date and time of its next conference call shall be announced after the agreement with AMAG Pharmaceuticals comes to conclusion.
